See more : Oil Refineries Ltd. (ORL.TA) Income Statement Analysis – Financial Results
Complete financial analysis of CM Life Sciences, Inc. (CMLF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CM Life Sciences, Inc., a leading company in the Shell Companies industry within the Financial Services sector.
You may be interested
- Man Sang International Limited (MSGNF) Income Statement Analysis – Financial Results
- JMT Auto Limited (JMTAUTOLTD.NS) Income Statement Analysis – Financial Results
- SHIVA SUITINGS LTD. (SHVSUIT.BO) Income Statement Analysis – Financial Results
- Seven Oaks Acquisition Corp. (SVOKW) Income Statement Analysis – Financial Results
- Southwestern Energy Company (SWN) Income Statement Analysis – Financial Results
CM Life Sciences, Inc. (CMLF)
About CM Life Sciences, Inc.
CM Life Sciences, Inc. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company was founded in 2020 and is based in New York, New York.
| Metric | 2020 |
|---|---|
| Revenue | 0.00 |
| Cost of Revenue | 0.00 |
| Gross Profit | 0.00 |
| Gross Profit Ratio | 0.00% |
| Research & Development | 0.00 |
| General & Administrative | 206.20K |
| Selling & Marketing | 0.00 |
| SG&A | 206.20K |
| Other Expenses | 0.00 |
| Operating Expenses | 206.20K |
| Cost & Expenses | 206.20K |
| Interest Income | 0.00 |
| Interest Expense | 0.00 |
| Depreciation & Amortization | 13.95K |
| EBITDA | -192.24K |
| EBITDA Ratio | 0.00% |
| Operating Income | -206.20K |
| Operating Income Ratio | 0.00% |
| Total Other Income/Expenses | 13.95K |
| Income Before Tax | -192.24K |
| Income Before Tax Ratio | 0.00% |
| Income Tax Expense | 0.00 |
| Net Income | -192.24K |
| Net Income Ratio | 0.00% |
| EPS | 0.00 |
| EPS Diluted | 0.00 |
| Weighted Avg Shares Out | 55.34M |
| Weighted Avg Shares Out (Dil) | 55.34M |
CM Life Sciences and Sema4 Announce Release of Definitive Proxy Statement for July 21 Shareholder Meeting to Vote on Business Combination
NEW YORK--(BUSINESS WIRE)--CM Life Sciences (Nasdaq: CMLF), a special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, has filed its definitive proxy statement with the Securities and Exchange Commission (the “SEC”) in...
3 Stocks Cathie Wood Keeps Buying
After every trading session, Ark Invest's Cathie Wood shows which stocks she has bought and sold throughout the day.
Sema4 and CM Life Sciences Announce the Filing of Amended Preliminary Proxy Statement
STAMFORD, Conn.--(BUSINESS WIRE)---- $CMLF #AI--The filing of the amended proxy statement marks the next step in the formal Securities and Exchange Commission (SEC) review process.
Cathie Wood's ARK Invest Buys Over 330,000 Shares of CM Life Sciences
One of ARK Invest exchange-traded funds run by ETF star Cathie Wood bought over 330,000 shares of CM Life Sciences Inc.
Sema4 and CM Life Sciences Announce the Filing of the Schedule-14A Proxy Statement in Connection with the Proposed Merger
STAMFORD, Conn.--(BUSINESS WIRE)---- $CMLF #AI--Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, and CM Life Sciences (Nasdaq: CMLF), a special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and...
CM Life Sciences Announces Filing of Amended Annual Report on Form 10-K Relating to Restatement of Financial Statements in Accordance with Recent SEC Guidance
NEW YORK--(BUSINESS WIRE)--CM Life Sciences, Inc. (NASDAQ:CMLF) today announced that it has filed with the Securities and Exchange Commission (SEC) an amended annual report on Form 10-K/A and a Form 8-K reporting the restatement of certain of its previously issued...
CM Life Sciences II: SomaLogic Is Great, But Post-Merger SPAC Dilution Should Frighten Investors
CM Life Sciences II, Inc. is the second life-sciences-focused special purpose acquisition company from the Casdin-Meisters team launched in Feb 2021.
CM Life Sciences: SPAC Acquires Sema4, A Promising AI Health Intelligence Co.
CM Life Sciences, Inc. is a life-sciences-focused special purpose acquisition company founded in July 2020 aiming to deploy $443M in raised cash to acquire a private company. CM LS selected their target, Sema4, a revenue-producing ('20: $190M|38% CAGR) health intelligence...
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of CM Life Sciences, Inc. - CMLF
NEW YORK, Feb. 12, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the...
CMLF Stock Price Increases Over 80% Over The Past Week: Why It Happened
The stock price of CM Life Sciences Inc (NASDAQ: CMLF) is trading up over 80% over the past week. This is why it happened.
Source: https://incomestatements.info
Category: Stock Reports